EUVIMEDEUVIMED entdecken
Crossref

Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens

Fátima Brañas iD, M José Galindo iD, Miguel Torralba iD, Antonio Antela, María Luisa Montes iD, M Jesús Bustinduy, Noemí Cabello iD, Alfonso Cabello iD, Margarita Ramírez iD, Pablo Ryan iD, Iñigo Bustingorri, Isabel Machuca iD und 1 weitere

HIV Medicine · 2026-11 · 27 (11) · 1896-1902

DOI: 10.1111/hiv.70310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 17.09.2026. Verfasst von Fátima Brañas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Infanta Leonor, Madrid, Spain. Hauptthemen laut MEDLINE: Piperazines, Pyridones, HIV Infections, Heterocyclic Compounds, 3-Ring. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on adults aged ≥60 years with HIV remain limited, despite their increasing representation in clinical practice. We evaluated whether age ≥60 years was associated with reasons for treatment switch, quality of life (QoL) and clinical outcomes among adults with HIV switching antiretroviral therapy in routine care.

Methods

We performed a cross‐sectional analysis of prospectively collected data from a real‐world cohort established in 2018, including adults with HIV aged ≥50 years who switched to bictegravir‐based three‐drug regimens (BIC 3DR) or dolutegravir‐based two‐drug regimens (DTG 2DR). Participants were stratified by age (≥60 vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPyridonesHIV InfectionsHeterocyclic Compounds, 3-RingQuality of LifeOxazinesDrug SubstitutionHeterocyclic Compounds, 4 or More RingsAnti-HIV AgentsHumansMiddle AgedFemaleMaleDolutegravirCross-Sectional StudiesAgedProspective StudiesAge FactorsAmides

Stichwörter der Autor:innen

HIVcomorbiditiesdual therapyolder adultsquality of lifetriple therapy

Substanzen

PiperazinesPyridonesHeterocyclic Compounds, 3-RingDolutegravirOxazinesbictegravirHeterocyclic Compounds, 4 or More RingsAnti-HIV AgentsAmides

Autor:innen und Institutionen

  • Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Hospital General Universitario de Valencia, Valencia, Spain.
  • Hospital Universitario de Guadalajara, Guadalajara, Spain.
  • Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Hospital Universitario La Paz, Madrid, Spain.
  • Hospital Universitario Donostia, San Sebastián, Spain.

ORCID-Profile: Fátima Brañas, M José Galindo, Miguel Torralba, María Luisa Montes, Noemí Cabello, Alfonso Cabello, Margarita Ramírez, Pablo Ryan, Isabel Machuca, Matilde Sánchez-Conde

Förderung

  • Gilead Sciences

Zitieren

APA

Brañas, F., Galindo, M. J., Torralba, M., Antela, A., Montes, M. L., Bustinduy, M. J., Cabello, N., Cabello, A., Ramírez, M., Ryan, P., Bustingorri, I., Machuca, I., & Sánchez-Conde, M. (2026). Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens. HIV Medicine, 27(11), 1896-1902. https://doi.org/10.1111/hiv.70310

Vancouver

Brañas F, Galindo MJ, Torralba M, Antela A, Montes ML, Bustinduy MJ, et al. Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens. HIV Medicine. 2026;27(11):1896-1902. doi:10.1111/hiv.70310

BibTeX
@article{Braas2026,
  author = {Brañas, Fátima and Galindo, M José and Torralba, Miguel and Antela, Antonio and Montes, María Luisa and Bustinduy, M Jesús and Cabello, Noemí and Cabello, Alfonso and Ramírez, Margarita and Ryan, Pablo and Bustingorri, Iñigo and Machuca, Isabel and Sánchez-Conde, Matilde},
  title = {Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens},
  journal = {HIV Medicine},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {1896--1902},
  doi = {10.1111/hiv.70310}
}
Kostenlos starten →